The Investor
04 Nov 2025, 06:09
Hims & Hers delivers 49% revenue growth and record profitability in Q3 2025
Hims & Hers Health (NYSE: HIMS) reported Q3 2025 revenue of nearly $600 million, up 49% year over year, with net income of approximately $16 million and record adjusted EBITDA exceeding $78 million, up 53%. The company’s subscriber base reached nearly 2.5 million, a 21% annual increase, reflecting growing demand for its personalized telehealth services. CEO Andrew Dudum emphasized expanding care offerings and partnerships as the platform evolves into a global health brand. CFO Yemi Okupe highlighted strong profitability and scaling efficiency, noting the company’s confidence in surpassing its long-term growth targets. Hims & Hers narrowed full-year 2025 guidance to $2.335–$2.355 billion in revenue and $307–$317 million in adjusted EBITDA.
Hims & Hers Health (NYSE: HIMS) reported Q3 2025 revenue of nearly $600 million, up 49% year over year, with net income of approximately $16 million and record adjusted EBITDA exceeding $78 million, up 53%. The company’s subscriber base reached nearly 2.5 million, a 21% annual increase, reflecting growing demand for its personalized telehealth services. CEO Andrew Dudum emphasized expanding care offerings and partnerships as the platform evolves into a global health brand. CFO Yemi Okupe highlighted strong profitability and scaling efficiency, noting the company’s confidence in surpassing its long-term growth targets. Hims & Hers narrowed full-year 2025 guidance to $2.335–$2.355 billion in revenue and $307–$317 million in adjusted EBITDA.
